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ABSTRACT 
Smoking cessation is of current topical interest due to the significant negative health and 
economic impact in many countries. This study aimed to develop buccal films and wafers 
comprising HPMC and sodium alginate (SA) for potential use in nicotine replacement 
therapy via the buccal mucosa, as a cheap but effective alternative to currently used nicotine 
patch and chewing gum. The formulations were characterised using texture analyser (tensile 
and hardness, mucoadhesion), scanning electron microscopy, x-ray diffractometry, attenuated 
total reflection – Fourier transform infrared (ATR-FTIR), differential scanning calorimetry 
(DSC) and swelling capacity. Drug loaded films and wafers were characterised for content 
uniformity (HPLC) whilst the drug loaded wafers only were further characterised for in vitro 
drug dissolution. SA modified and improved the functional properties of HPMC at optimum 
ratio of HPMC: SA of 1.25 : 0.75. Generally, both films and wafers (blank and drug loaded) 
were amorphous in nature which impacted on swelling and mucoadhesive performance. 
HPMC-SA composite wafers showed a porous internal morphology with higher 
mucoadhesion, swelling index and drug loading capacity compared to the HPMC-SA 
composite films which were non-porous. The study demonstrates the potential use of 
composite HPMC-SA wafers in the buccal delivery nicotine. 
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1. Introduction 
The buccal mucosa has become a very attractive route of drug delivery especially for drugs 
with low bioavailability, poor gastrointestinal stability and susceptibility to first pass 
metabolism including proteins and peptides [1] by delivering the drug directly into the 
bloodstream. Although the parental route offers a similar solution, it can be inconvenient to 
administer due to the pain associated with piercing the skin and requires a trained personnel 
to perform the task [2, 3]. The transdermal route can also allow the delivery of drugs directly 
into the bloodstream and has been used in commercial nicotine replacement therapy (NRT) in 
the form of transdermal patches. Transdermal patches, however, take longer time to achieve a 
smoker’s saturation peak [4] which result in non-compliance.  
Nicotine (NIC) is the major component of tobacco used in cigarettes. It is a volatile, alkaline 
liquid and colourless in nature, highly soluble in both water and other organic solvents with 
two well separated pKa values (3.04 and 7.84) resulting in different charge species depending 
on the medium pH. Both charged species can be readily absorbed across the skin and mucosal 
surfaces [5]. 
The physiological and psychomotor symptoms associated with smoking cessation, 
such as irritability, sleepiness, sleeplessness, unsteadiness, regular coughing, mouth blisters, 
constipation, chest stiffness and continuous cigarette craving, have been managed using 
various NRTs. NIC cannot be developed as an oral pill because of its susceptibility to first 
pass metabolism in the liver, which can retard bioavailability [6, 7]. As a result, different 
drug delivery strategies have been explored for NRT to increase NIC absorption. These 
include transdermal patches, chewing gums, lozenges, mouth sprays and nasal spray. These 
products have been licensed in several countries including UK and Canada to help reduce 
withdrawal symptoms in the temporary abstinence periods that can usually arise in places 
where smoking is prohibited e.g. in airplanes, trains or hospitals [8]. 
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Films and wafers have extensively been investigated as buccal drug delivery systems. 
Films are usually prepared by solvent evaporation method [9, 10] while wafers are prepared 
by a sublimation process known as freeze-drying [11]. There has been research reported on 
the delivery of NIC via the buccal route using films [12-14]. Pongjanyakul and Suksri 
reported the use of SA and magnesium aluminium silicate (MAS) clay films in the buccal 
mucosal delivery of NIC and demonstrated a promising use of NIC loaded SA-MAS films as 
mucosal delivery systems [15]. On the other hand, wafers have been employed as wound 
healing [16] and buccal [18] drug delivery systems. They can therefore be employed in the 
delivery of NIC, including composite systems combining two or more polymers [16, 17] as 
demonstrated by Pawar and co-workers [18, 19] who reported the use of composite polymeric 
wafers combining polyox with either carrageenan or sodium alginate in the development of 
wafers for controlled delivery of drugs to chronic wound sites [18, 19]. 
Films and wafers can possess adhesive properties when formulated with 
mucoadhesive polymers such as HPMC and sodium alginate (SA). The properties of 
mucoadhesive polymers such as surface charge and solubility play a vital role in their ability 
to adhere to mucosal surfaces. Charged polymers such as SA demonstrate higher adhesion 
than non-ionic polymers (e.g. HPMC), because of their ability to form a strong electrostatic 
interaction with the charged surface of mucin [20]. The use of composite polymeric systems 
can be adopted to enhance the functional properties of a polymeric dosage form. HPMC is 
very effective in designing controlled drug delivery systems while SA can be used to enhance 
the mucoadhesion of a given polymeric dosage form. Further, the anionic nature of SA 
provides a potential means of interaction of the amine groups of NIC with the carboxylic acid 
side chains of SA, which could improve mucoadhesion and provide further control of drug 
release. [5, 24].  
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Functional properties such as tensile (films), hardness (wafer), hydration, adhesion, 
and drug release are important characteristics of a buccal formulation that can influence its 
performance. For example, elasticity, flexibility and softness are essential properties to be 
considered in film formulation as a result of stress from mouth motions which the film needs 
to be able to withstand [21]. 
In this study, we report on the formulation development and comparison of solvent 
evaporated films and freeze-dried wafers combining HPMC and SA as mucoadhesive 
systems for potential NRT via the buccal mucosa. The formulations have been characterised 
using texture analysis, scanning electron microscopy, X-ray diffraction (XRD), attenuated 
total reflection – Fourier transform infrared (ATR-FTIR) spectroscopy differential scanning 
calorimetry (DSC) and high-performance liquid chromatography (HPLC) for 
mechanical/hardness, surface/internal morphology, crystallinity, chemical interactions, 
thermal, drug content/release properties respectively. The swelling profiles were also 
determined by calculating the swelling index for hydration and water holding capacity. The 
characterisation data was used to compare the properties of different HPMC-SA composite 
films and wafers as well as compare HPMC-SA films and wafers. The selected optimised 
formulation (wafer) was then further characterised for drug dissolution behaviour. 
 
2. Experimental 
2.1 Materials 
The materials used in this experiment included; HPMC (Methocel K100 premium LV) obtained as a 
gift from Colorcon Limited (Dartford, UK). Sodium hydroxide, potassium dihydrogen phosphate and 
gelatine were all purchased from Fluka Analytical (Buchs, Switzerland); Nicotine (liquid form), sodium 
alginate, and mucin from porcine stomach were obtained from Sigma-Aldrich (Dorset, UK). Sodium 
acetate, trimethylamine and glycerol were all purchased from Fisher Scientific (Loughborough, UK). 
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2.2 Preparation of composite films 
Blank (BK) viscous polymeric solutions were prepared by dissolving HPMC, sodium alginate 
(SA) and glycerol (GLY) in 100ml of distilled water at 25°C. The resulting polymeric 
solutions were left to stand overnight to remove all air bubbles, 30g was poured into a Petri 
dish (90mm diameter) and dried in an oven at 30°C for 18-20 hrs. Drug loaded (DL) films 
were prepared as above with the addition of NIC to the polymeric solutions before drying in 
the oven. The concentrations of polymers, plasticizer and drug used in each viscous 
polymeric solution have been summarised in Table 1a. 
 
2.3 Preparation of composite wafers 
Viscous polymeric solutions for BK and DL wafers were prepared in similar manner as for 
the films but without using GLY. The polymeric solutions (1g) were poured into each well of 
a 24 well plate (diameter 15.5mm). The concentrations of polymers and drug present in each 
polymeric solution are summarised in Table 1b. The freeze-dried wafers were prepared using 
an automated lyophilisation cycle on a Virtis Advantage XL 70 freeze-dryer (Biopharma 
process systems, Winchester, UK). The well plates containing the polymeric solutions were 
loaded onto the shelves of the freeze-dryer and programmed for freezing, primary drying and 
secondary drying steps. The freezing step involved cooling the sample from room 
temperature to 5°C (40 mins), 5°C to -10°C (40 mins), and then from -10°C to -55°C (120 
mins). An annealing step was incorporated into the freezing cycle in other to improve pore 
size distribution by increasing the temperature from -55°C to -35°C (2 hrs) and then cooling 
back down to -55°C (3 hrs). Additional freezing was performed to ensure uniformity by 
freezing at -55°C (1 hr) with a condenser temperature of -55°C and pressure of 200mTorr. 
The primary drying occurred under high pressure of 50mTorr, with temperature raised from -
55°C to -20°C (8 hrs) and further increased from -20°C to -15°C ° (10 hrs). Secondary drying 
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occurred at the same pressure as primary drying but increasing the temperature from -15°C to 
25°C (12 hrs 30 mins).  
 
2.4 Texture (TA) analysis 
2.4.1 Tensile properties of films 
The tensile properties of the films were analysed using a texture analyser (HD plus, Stable 
Micro System, Surrey, UK) equipped with a 5 kg load cell. Prior to obtaining tensile data, the 
BK and DL films were cut into dumb-bell shaped strips and the thickness of films was 
measured using a micrometre screw gauge. The films were fixed in between two tensile grips 
of the TA instrument and then stretched at a test speed of 2mm/sec till breaking point.  The 
elongation at break (%), tensile strength and elastic modulus was determined using equations 
1, 2 and 3 respectively (n=3) [22]. 
𝐸𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑏𝑟𝑒𝑎𝑘(%) =
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑓𝑖𝑙𝑚 𝑙𝑒𝑛𝑔𝑡ℎ
× 100 (1) 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ =
𝑝𝑒𝑎𝑘 𝑓𝑜𝑟𝑐𝑒 𝑎𝑡 𝑏𝑟𝑒𝑎𝑘
𝑐𝑟𝑜𝑠𝑠−𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑙𝑚
 (2) 
𝐸𝑙𝑎𝑠𝑡𝑖𝑐 𝑚𝑜𝑑𝑢𝑙𝑢𝑠 =
𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑡𝑟𝑒𝑠𝑠−𝑠𝑡𝑟𝑎𝑖𝑛 𝑐𝑢𝑟𝑣𝑒
𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (𝑓𝑖𝑙𝑚)×𝑐𝑟𝑜𝑠𝑠 ℎ𝑒𝑎𝑑 𝑠𝑝𝑒𝑒𝑑
 (3) 
 
2.4.2 Mechanical properties of wafers (hardness) 
The resistance to compressive deformation (hardness) of the freeze dried wafers was 
determined using a texture analyser (HD plus, Stable Micro System, Surrey, UK) equipped 
with a 5 kg load cell. The BK and DL wafers were compressed on 5 different locations of 
each wafer (n = 3), using a 2mm cylinder stainless steel probe to a depth of 2 mm at a speed 
of 1mm/sec with the instrument in compression mode. 
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2.5 Scanning electron microscopy (SEM) analysis 
The surface morphology of both BK and DL films and wafers were analysed using a Hitachi 
SU8030 (Hitachi High-Technologies, Krefeld, Germany) scanning electron microscope. 
Films and wafers were cut into small strips and placed on Agar Scientific G301 aluminium 
pin-type stubs, using Agar Scientific G3347N double-sided adhesive carbon tape. The films 
were chromium coated, while wafers were gold coated for clearer pore image using a Sputter 
Coater (Edwards 188 Sputter Coater S1508). Films were analysed at 2.0kV accelerating 
voltage while wafers were analysed at 5.0kV accelerating voltage. 
 
2.6 Wafer pore analysis  
Wafer pore analysis was used to evaluate the porosity of HPMC-SA wafer structure. The 
wafers were initially weighed and then immersed in 5ml of ethanol in a glass vial and was 
left to stand for 10 mins. The vials with ethanol and wafers were degassed to remove air 
bubbles trapped inside the wafers for 10 mins. After degassing, the wafers were carefully 
removed from the solvent, wiped to remove excess solvent, and immediately weighed to 
avoid loss of ethanol due to its volatility. 
The percentage porosity of wafers was calculated using equation 4 below: 
𝑃 =  
𝑉𝑝
𝑉𝑔
 × 100 =
𝑊𝑓−𝑊𝑖
𝜌𝑒𝑉𝑔
 (4) 
Where 
Vp = pore volume 
Vg = wafers geometrical volume 
Wf = final weight of wafer  
Wi = initial weight of wafer  
ρe = ethanol density (0.789 g/cm3) 
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2.7 X-ray diffraction (XRD) analysis 
The physical (crystalline/amorphous) form of both BK and DL films and wafers was 
investigated using a D8 Advantage X-ray diffractometer. Films were cut into small pieces 
whilst wafers were compressed using two clean cover glasses, placed on the holder and 
mounted onto the sample cell. For pure starting materials, mylar was used to hold the 
powders before placing on the sample cell. The samples were analysed in transmission mode 
at a diffraction angle ranging from 5° to 50° 2θ, step size 0.04°, and scan speed of 0.4s/step. 
 
2.8 Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) 
analysis 
ATR-FTIR spectra were obtained from a Perkin Elmer Spectrum instrument which was 
equipped with a diamond universal ATR-unit. The composite films and wafers were cut into 
strips, placed on the ATR diamond crystal and force applied using a pressure clamp to allow 
adequate contact between the sample and diamond crystal. Pure solid samples (i.e. HPMC 
and SA) were also examined in a similar way as the films and wafers. For NIC, there was no 
force applied as the liquid could form intimate contact with the diamond crystal without any 
applied force. The resolutions of the samples were recorded at 4 cm-1 within the range of 450-
4000 cm-1. Background spectra were subtracted in other to obtain a reliable absorbance of 
each sample. 
 
2.9 Differential scanning calorimetry (DSC) analysis 
A DSC Mettler Toledo instrument was used to thermally analyse pure samples as well as BK 
and DL films and wafers. Films and wafers were weighed (between 1-3mg), placed in Tzero 
pans and covered with Tzero hermetic lids. The samples were heated from -50°C to 250°C at 
the rate of 10°C/min under constant purge of nitrogen. 
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2.10 Swelling studies 
The swelling capacities of both BK and DL films and wafers were determined by immersing 
each formulation into 5ml of phosphate buffer (pH 6.8). The percentage swelling index was 
investigated by recording change in weight at time intervals of 2 mins up to 30 mins. For 
every time point, the medium was carefully removed to obtain an accurate weight of the 
sample and replaced with fresh medium. Three replicates were performed for each sample 
and swelling index (%) was calculated using equation 5 [23]. 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 =
𝑊𝑠−𝑊𝑑
𝑊𝑑
× 100 (5) 
Where Wd = dry weight of polymeric film / wafer. 
  Ws = weight of film/wafer after swelling. 
 
2.11 Mucoadhesion studies 
Adhesion test was performed on BK and DL films and wafers using a TA. HD plus Texture 
Analyser (Stable micro systems, Surry, UK) in tensile mode and fitted with a 5kg load cell. 
Films were cut considering the mathematical area of wafers (a circle with diameter = 
15.5mm). The films and wafers were attached to an adhesive probe (75mm diameter) of the 
TA instrument using a double-sided adhesive tape. Gelatine gel (6.67% (w/v)) was prepared 
by dissolving gelatine in water at 70°C, poured into a Petri dish (86mm diameter) and placed 
in a fridge overnight to set into solid gel to represent the buccal mucosa surface. Mucin 
solution (2% w/v) was prepared by dissolving mucin powder from porcine stomach in a 
phosphate buffer (pH 6.8) and 0.5ml evenly spread on the surface of the set gelatine gel. 
Using the TA analyser, the probe with film or wafer attached was lowered to make contact 
with the model buccal mucosa surface and was detached after the contact time of 60 sec with 
an applied force of 1.0N. Mucoadhesive strength was determined by the maximum adhesive 
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force (Fmax) required to detach the sample from the model buccal surface, work of adhesion 
was determined by the area under the force-distance curve, while cohesiveness represents the 
distance the films/wafers travelled till they detached from the model buccal surface. Texture 
Exponent 32® software was used in collecting and processing the data from the texture 
analyser. 
 
2.12 HPLC analysis 
NIC was analysed by HPLC using an Agilent 1200 HPLC instrument (Agilent Technologies, 
Cheshire, UK) with an auto sampler. The stationary phase used was a C-18 reverse-phase 
column, 4.6 x 250mm (Phenomenex HPLC column, Cheshire, UK). Trimethylamine, 
methanol and sodium acetate (88:12:0.5 v/v) were used as mobile phase pH adjusted to 4.2 
using glacial acetic acid, at a flow rate of 1ml/min and UV detection at 259nm15. The 
retention time of NIC was detected at approximately 4.5 min. Calibration curve was plotted 
using standards with NIC concentration ranging from 40µg/ml to 400µg/ml (R2=0.9994). 
 
2.13 Drug content (% loading and recovery) 
The content of NIC in DL films and wafers was assayed, by accurately weighing both DL 
films and wafers and dissolving in 10ml of distilled water. The resulting film/wafer solution 
was collected into a syringe, filtered through a 0.45µm cellulose acetate membrane, 
transferred into HPLC vials and placed in HPLC sample chamber and analysed as described 
above (n=3). 
 
2.14 In vitro drug dissolution 
In vitro drug dissolution of DL wafers was performed with the help of a Franz-diffusion cell 
apparatus. The receptor compartment was filled with 8ml of phosphate buffer (pH 6.8) with a 
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mesh on the receptor surface. The donor and receptor compartments were sealed with 
paraffin, to limit evaporation and held together by a pinch clamp. The system was placed on a 
water bath at 37°C with magnetic stirring at approximately 200rpm. The wafer samples were 
weighed and placed on the mesh between the donor and receptor compartments. At 
predetermined time intervals, 0.5ml aliquots of the dissolution media were withdrawn using a 
1ml syringe, filtered through a 0.45µm cellulose acetate membrane, transferred into HPLC 
vials and analysed using HPLC. Each aliquot withdrawn at each time point, was replaced 
with fresh buffer solution, in order to maintain a constant volume of dissolution media. The 
percentage drug released from wafers was calculated and plotted against time (n=3). 
 
2.15 Statistical analysis 
Statistical analysis was performed using student t-test and / or one-way ANOVA to compare 
the results. The results were expressed as mean ± standard deviation and significant 
differences were determined at a level of p < 0.05. 
 
3 Results  
3.1. Formulation development 
 
Films 
BK unplasticised HPMC film with no SA was highly brittle and therefore was difficult to 
remove from the Petri dish. As a result, GLY was added to the polymeric solutions to reduce 
brittleness and increase flexibility of the final films. The optimum concentration of GLY (2% 
w/v) present in the polymeric solutions for the BK HPMC film was selected based on texture 
analysis and SEM analysis.  
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Polymeric solutions of plasticised composite HPMC-SA films were easy to pour and 
were easy to remove from the Petri dish after oven drying. DL HPMC-SA films were much 
easier to remove from Petri dishes than BK HPMC-SA film. All HPMC-SA films were 
transparent but as concentration of SA increased, the film showed a light yellowish colour 
imparted by pure SA powder. 
Wafers 
HPMC wafers formulated by lyophilisation were easily removed from well plates, easy to 
handle and were intact, therefore there was no need to use plasticiser to enhance their 
physical and handling properties unlike the films. 
 
3.2 Texture analysis (TA) 
 
3.2.1 Tensile properties of films 
Texture analysis was used to analyse the mechanical properties of the films. The effect of 
GLY is demonstrated in Figure 1. As concentration of GLY in the original HPMC solution 
increased from 0% w/v to 4% w/v there was decrease in brittleness and stiffness, as well as 
increase in elasticity which are related to tensile strength in Figure 1(a), elastic modulus 
Figure 1(b) and elongation at break (%) Figure 1(c) respectively. Highly plasticised BK 
HPMC films prepared from polymeric solutions containing more than 2% w/v GLY 
demonstrated very low tensile strength and elastic modulus as well as very high elongation at 
break, which are undesirable and can result in difficulty in handling of the film due to their 
sticky nature. 
Figure 2 also shows the tensile strength (brittleness), elastic modulus (stiffness) and % 
elongation at break (elasticity) results of BK and DL composite HPMC-SA films. The tensile 
strength of both BK and DL composite HPMC-SA films (Figure 2a) remained constant as the 
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amount of SA increased. This implies that there is no effect of SA concentration on the t 
brittleness of BK and DL HPMC-SA composite film. However, DL HPMC-SA composite 
film showed significantly (p = 0.0028) higher tensile properties than BK HPMC-SA 
composite film. 
BK composite HPMC-SA films showed a decrease in elastic modulus (Figure 2b) as SA content 
increased from 0.25 to 0.75, however, the elastic modulus for BK films with no SA (SA 0.00) 
(12.42±1.46 N/mm2) and BK SA 0.25 (12.42±1.20 N/mm2) remained the same in BK HPMC-SA 
composite films. On the contrary DL HPMC-SA composite films showed a significantly (p=0.0334) 
lower elastic modulus than BK HPMC-SA composite film as well as an increase in elastic modulus as 
SA concentration increased. A significant difference (p=0.0019) was also observed between the 
elongation at break (%) of BK HPMC-SA films and DL HPMC-SA films (Figure 2c) with the highest 
elongation at break (%) observed for films containing SA 0.75 in both BK (39.62±2.99%) and DL 
(52.63±4.27%) HPMC-SA composite films. 
 
3.2.2 Mechanical properties of wafer (hardness) 
Texture analysis was used to determine the resistance to compressive deformation (hardness) 
of the BK and DL HPMC-SA wafers. Figure 3 shows the hardness profiles of BK and DL 
HPMC-SA wafers containing different ratios of both polymers. DL HPMC wafer (SA 0.00) 
demonstrated higher resistance to compression with a peak force of 1.50±0.13N than BK 
HPMC (SA 0.00) wafers with a peak resistance force of 1.27±0.10N. The BK HPMC-SA 
wafers demonstrated a slight decrease in the hardness for HPMC-SA composite wafer 
containing the lowest amount of SA (i.e. SA 0.25) when compared to HPMC alone (i.e. SA 
0.00), but started to increase for subsequent HPMC-SA composite wafers containing SA 0.50 
and 0.75. On the other hand, DL HPMC-SA wafers showed a decrease in hardness with 
increase in SA concentration from 1.50±0.13N for HPMC only wafer (i.e. SA 0.00) to 
1.06±0.06N for DL composite wafers containing SA 0.75. The comparison between BK and 
DL HPMC-SA wafers, however, did not demonstrate any significant difference (p = 0.775). 
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3.3 Scanning electron microscopy (SEM)  
Surface morphology of BK HPMC only films with different concentrations of GLY are 
shown in Figure 4(i), confirming that the surface structures of the film demonstrated the 
undesired observed stickiness of highly plasticised BK HPMC films. A GLY concentration of 
2% w/v within the polymeric solutions was therefore selected as the optimum to prepare BK 
HPMC films. SEM images showing surface morphology of composite BK films and internal 
structure of composite BK wafers are shown in Figures 4(ii) and 5 respectively. Films 
showed smooth topography especially for HPMC-SA films with higher SA concentration 
(Figures 4(ii)(c) and (d)), however, films with lower SA (Figure 4(ii)(a)) showed a rough 
surface. SA 0.25 films (Figure 4(ii)(b)) showed cracks on the surface and could be due to a 
lack of proper blending between SA and HPMC as well as poor mechanical properties. 
Wafers on the other hand showed a sponge-like and porous internal morphology as a result of 
ice nucleation formed during freeze-drying (Figure 5). HPMC-SA composite wafers with low 
SA concentration (SA 0.25) in Figure 5(b) showed collapsed pores but as SA concentration 
increased, the wafers appeared less collapsed as shown in Figure 5(c) and (d). 
 
3.4 Wafers pore analysis 
Wafer pore analysis was performed to complement the SEM analysis with the aim of semi-
quantitatively analysing the porosity of the wafers with different SA content in composite 
HPMC-SA formulations. The result of the porosity (%) ranged from 61 – 74%, with the 
porosity increasing as SA content increased within the formulations. The porosity results 
however, confirms the less collapsed pores of wafers containing higher amounts of SA (SA 
0.50 and 0.75). 
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3.5 XRD analysis 
Figure 6(a) shows XRD transmission diffractograms of pure polymers (SA and HPMC) and 
mylar (used in pure powder preparation to hold the powder and prevent it from spilling). The 
results show the amorphous nature of SA with a broad peak at 2θ 14° and 22°, whilst HPMC 
also showed a broad peak at 2θ 20°. Figures 6(b) and 6(c) shows the XRD transmission 
diffractograms of BLK HPMC-SA and DL HPMC-SA films respectively. Both BK and DL 
HPMC-SA films and wafers exhibited an amorphous nature, with a broad peak around 2θ of 
20°. However, the wafers also showed a small crystalline shoulder peak at 2θ of 23°.  Given 
that this peak was not present in the films, it could be attributed to false peak detection arising 
from compression of the wafers which causes the leafy networks to be piled up on top of each 
other and detected as a false crystalline peak. However, this might require further 
investigation to rule out possibility of trace amounts of other material naturally present in one 
of the polymers. 
 
3.6 Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) 
analysis. 
The major peaks from the ATR-FTIR spectra of pure powders, BK and DL HPMC-SA 
composite films and BK and DL HPMC-SA composite wafers are summarised in Figure 7. 
The characteristic peaks of SA, HPMC and GLY can be seen in Figure 7a. BK HPMC-SA 
composite films (Figure 7b) showed a shift to lower wavenumbers for OH stretching 
vibration as SA concentration increased except for BK SA 0.25 film, which showed a much 
higher OH stretching vibration band at 3370cm-1. Hydrogen bonding in COO groups was also 
observed at higher SA concentration as evidenced by shifting to lower wavenumber from 
1647 cm-1 to 1607 cm-1 for COO- asymmetric stretching and the disappearance of the peak 
for COO- symmetric stretching (composite BK HPMC: SA 0.50 films) at 1455 cm-1 present 
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from the spectra of the composite BK HPMC: SA 0.75 films. The shift in C-CH3 bending was 
a result of GLY present in the HPMC-SA composite films. DL HPMC-SA films (Figure 7c) 
also showed a shift in OH stretching vibration to lower bands as SA concentration increased 
except for SA 0.50 film at 3340cm-1 which showed similar OH vibration with HPMC only 
film (i.e. SA 0.00).  
Characteristic peaks for BK HPMC-SA composite wafers are summarised in Figure 7d. The results 
showed a shift to lower wavenumber, with increase in SA concentration, for OH stretching (SA 0.00: 
3414 cm-1; SA 0.25: 3402 cm-1; SA 0.50: 3401 cm-1 and SA 0.75: 3393 cm-1). There was also a shift to 
lower wavenumbers for COO- asymmetric vibrations (SA 0.00: 1647 cm-1; SA 0.25: 1615 cm-1; SA 
0.50: 1607 cm-1 and SA 0.75: 1605 cm-1). The COO- symmetric stretching vibrations were only present 
in SA 0.00 (1456cm-1) and SA 0.25 (1456cm-1) wafers. However, these were absent at higher 
concentrations of SA (SA 0.50 and 0.75). In addition, there was absence of COO- symmetric stretching 
vibration peaks in SA 0.00 wafers but present in SA 0.25, 0.50 and 0.75 wafers at 1413, 1412 and 
1412cm-1 respectively. DL HPMC-SA wafers exhibited similar changes in OH stretching (SA 0.00: 
3414 cm-1; SA 0.25: 3401 cm-1; SA 0.50: 3401 cm-1 and SA 0.75: 3393 cm-1) and COO- asymmetric 
stretching bands (SA 0.00: 1647 cm-1; SA 0.25: 1616 cm-1; SA 0.50: 1607 cm-1 and SA 0.75: 1604 cm-
1) as noticed in BK HPMC-SA wafers. However, DL HPMC-SA wafers (Figure 7e) demonstrated 
changes in C-CH3 bending with absence of C-CH3 bending peak in wafers containing higher SA 
concentrations (SA 0.50 and 0.75 wafers). 
 
3.7 DSC analysis 
DSC analysis was used to investigate the thermal properties of pure polymer powders, and 
the HPMC-SA composite films and wafers. Figure 8 shows the thermal profiles of BK 
HPMC-SA films, DL HPMC-SA films, BK HPMC-SA wafers and DL HPMC-SA wafers at 
different SA concentrations. There were no glass transition peaks in the thermograms for both 
pure polymers (data not shown) or HPMC-SA films and wafers within the temperature range 
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analysed. However, endothermic transitions were observed between 50-90°C in the pure 
powders (data not shown) and HPMC-SA films and wafers, attributed to the loss of residual 
water from the polymer matrix. SA demonstrated a higher peak endothermic temperature in 
with a maximum peak temperature of 109.91°C (figure not shown) than HPMC powder with 
a maximum peak temperature of 81.16°C. 
BK HPMC films (i.e. BK SA 0.00) in Figure 8a showed the higher peak temperature 
at 89.63°C. However, subsequent BK HPMC-SA films decreased in peak temperature 
(between 76-80°C) as SA concentration increased (i.e. SA 0.25, 0.50 and 0.75). Similar to 
BK HPMC-SA films, DL HPMC films (DL SA 0.00) in Figure 8b also demonstrated 
endothermic peak temperature at 65.83°C but this increased (64-66°C) SA concentration 
increased at SA 0.25, 0.50 and 0.75 DL HPMC-SA films. In general, BK HPMC-SA films 
(Figure 8a) showed higher peak temperature compared to DL HPMC-SA films (Figure 8b). 
On the other hand, BK and DL wafers (Figures 8c & 8d) demonstrated an increase in 
endothermic peak temperature as SA concentration increased. BK and DL HPMC wafer (SA 
0.00) showed the lowest peak temperature at 54.94 and 53.3°C respectively. Both BK and DL 
HPMC-SA wafers showed maximum peak temperature between 60-72°C. 
 
3.8 Swelling studies 
Figures 9(a) and (b) show changes in swelling index of HPMC-SA films and wafers 
respectively with time. The swelling profile in Figure 9(a) demonstrate a decrease in swelling 
index (%) with increase in SA content within HPMC-SA films, while the swelling profile in 
Figure 9(b) demonstrate an increase in swelling index as SA increased for HPMC-SA wafers. 
However, there was no statistically significant difference between the different film 
formulations (p = 0.726, one-way ANOVA) as well as between the wafers (p=0.355, one-
way ANOVA). In addition, it can also be observed that while HPMC-SA films showed a 
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gradual increase in swelling index (%) with time, HPMC-SA wafers showed a more rapid 
increase in swelling index (%) within a short time (2 mins) and then remained constant over 
the duration of the study. 
 
3.9 Mucoadhesion studies 
Figures 10 and 11 show the mucoadhesion profiles of BK and DL HPMC-SA films, and BK 
and DL HPMC-SA wafers respectively obtained from the TA curves during the analysis.  
The peak adhesion force (PAF) or Fmax of BK and DL HPMC-SA films (Figure 10a) 
increased as SA concentration increased with a maximum value of 2.78±0.09N for BK 
HPMC-SA films and 1.94±0.13N for DL HPMC-SA films, containing SA 0.75.  The TWA 
(Figure 10b) and the cohesiveness (Figure 10c) of DL HPMC-SA films did not show a 
consistent profile for SA 0.25 and 0.50 formulation respectively, with higher error bars in 
both TWA and cohesiveness for SA 0.25 films and lower error bars in TWA and 
cohesiveness for SA 0.50 films. This suggest that the SA 0.25 formulation has poor 
interaction of HPMC and SA in the composite formulation and therefore not very reliable to 
take forward. However DL HPMC-SA film with higher SA concentration i.e. SA 0.75 film 
showed lower variability in TWA (1.98±0.50Nmm) and relatively high cohesion 
(2.42±0.53mm) than SA 0.50.   
The Fmax of BK HPMC-SA wafers remained constant (Figure 11a) as SA 
concentration increased while Fmax for DL HPMC-SA wafers increased as SA concentration 
increased. Further, BK HPMC-SA wafers showed lower Fmax than DL HPMC-SA wafers 
though the difference was not statistically significant (p=0.109). The TWA (Figure 11b) and 
cohesiveness (Figure 11c) of DL HPMC-SA showed an increase with initial SA 
concentration (SA 0.25), but decreased at maximum SA concentration (SA 0.75) while BK 
HPMC-SA wafers showed an increase in TWA and cohesiveness at maximum SA 
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concentration (SA 0.75). The increase in the Fmax and decrease in cohesiveness resulted in 
similar values of TWA for both BK and DL HPMC-SA wafers at maximum SA 
concentration (SA 0.75). In addition, the Fmax, TWA and cohesiveness of BK and DL HPMC-
SA wafers showed no statistically significant difference with p values of 0.109, 0.151 and 
0.902 respectively. Generally, the films demonstrated higher mucoadhesive values than 
wafers. 
 
3.10 Drug content (% loading / recovery) 
The films showed a very low percentage of NIC with a maximum assayed content below 
35% (SA 0.75, 28±4.09 %). On the other hand, the composite wafers yielded significantly 
higher NIC content above 75% (i.e. SA 0.00, 88±6.17 %; SA 0.25, 90±2.01 %; SA 0.50, 
78±1.854% and SA 0.75, 79±1.011%. However, increase in effective SA concentration 
resulted in a decrease in the percentage NIC content in the respective formulations (i.e. SA 
0.50, 78±1.854 and SA 0.75, 79±1.011%) as compared to DL HPMC-SA composite wafer 
with low SA concentration (i.e. SA 0.25, 90±2.01 %) and DL HPMC wafer with no SA 
present (i.e. SA 0.00, 88±6.17 %).  
 
3.11 In vitro drug dissolution 
Due to the very low drug contents observed in all the films, DL HPMC-SA films were 
discontinued from further analysis. Figure 12 shows the dissolution profiles of DL HPMC-
SA composite wafers. DL HPMC-SA composite wafers with the highest SA concentration 
(SA 0.75) showed the highest % cumulative drug release within 4 hrs as compared to other 
composite wafers with a significant difference (p=0.041, one-way ANOVA). The DL 
HPMC-SA composite wafers with the highest SA concentration released 92 ± 8% within the 
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first 30 mins and up to a 100% in 4 hrs in comparison with other HPMC-SA composite 
wafers, which released less than 60% within 4 hrs.  
 
4. Discussion 
The polymers used to prepare the composite films and wafers, were selected based on their 
mucoadhesive characteristics as well as their classification as GRAS. HPMC was selected 
based on its ability to control release of drug incorporated within a delivery system as well as 
its accessibility in regards to low cost of production [24]. SA on the hand was considered 
based on its mucoadhesive property as an anionic material, usually considered a better 
mucoadhesive polymer than non-ionic polymers such as HPMC [25, 26]. SA was also 
considered based on its ability to form ionic interactions by interacting with the positive 
charge of protonated NIC [15]. 
The dosage forms (i.e. solvent cast films and freeze-dried wafers) compared to 
determine drug loading efficiency due to the challenges posed by incorporating NIC, which is 
volatile into drug delivery systems. The consideration of plasticiser in films was the result of 
the brittleness and poor handling of unplasticised films during preliminary formulation 
development. The incorporation of plasticiser aids in increasing the free volume between the 
polymer chains (HPMC and SA) with the ability to slip past each other, resulting in more 
flexible films which are easy to handle [27]. The effect of plasticiser therefore decreased 
brittleness (tensile strength) and stiffness (elastic modulus) but increased elasticity 
(percentage elongation at break) in HPMC films. However, excess of plasticiser could result 
in higher free volume between polymers that are highly slippery and difficult to handle (very 
sticky) as shown in mechanical properties and SEM images of BK HPMC films obtained 
from polymeric solution with GLY above 2% w/v. Therefore a balance between flexibility 
and toughness with an optimum elongation ideally between 30-50% is desirable [28]. 
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Optimised concentration of GLY at 2% w/v within the original polymeric solution met the 
criteria of an ideal film based on its elongation and was therefore the concentration of choice 
in DL films. 
Wafers on the other hand did not show any difficulty in handling, due to the ability to 
control the thermal events during freeze drying cycle. The thermal programme used was 
essential in achieving a cake structure that can be easy to handle by improving the freezing, 
primary and secondary drying stages. Using a controlled freezing process incorporating an 
annealing step, the ice crystal size and distribution was improved leading to better sponge-
like pores preceding sublimation via primary and secondary drying [29]. 
HPMC and SA composite formulations formed a network polymeric matrix with a 
non-ionic interaction between the polymers. SA showed no plasticising effect on HPMC-SA 
composite films as the brittleness (tensile strength) of the films remained constant. However, 
NIC in the formulation increased the elongation but decreased the stiffness of the film while 
interacting with SA via ionic and hydrogen bonding. By this interaction, NIC increases the 
free volume between SA and HPMC thereby exhibiting a plasticising effect on the film. 
Handling of wafers is important during application and therefore optimised 
mechanical property is necessary. The resistance of wafers against compression deformation 
data permits the assessment of the reliability of wafer structure [30]. The increase in hardness 
of BK wafers at higher SA concentration was possible due to hydrogen bonding existing 
between the COO- group of SA and the OH group of HPMC, which may interrupt the 
polymeric matrix of HPMC and hence increased the resistance to compression forces but was 
limited for wafers with lower SA concentration (SA 0.25). Wafers loaded with NIC 
decreased in resistance to deformation, which can be attributed to the NIC causing a slight 
increase in free volume between HPMC and SA polymeric chains in the composite wafers as 
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observed in HPMC-SA composite films where there was increase in elasticity and decrease in 
stiffness. 
Hydration and swelling behaviour of a dosage form can influence the drug dissolution 
profile, since diffusion, swelling and erosion are the mechanisms by which drug release is 
controlled [24]. The amorphous properties of film and wafers as demonstrated in XRD results 
played a role in swelling, as amorphous materials are more mobile and hence improve the 
rate of dissolution [31]. The high swelling property of HPMC explains the higher swelling 
index of HPMC only films (i.e. SA 0.00 ) compared to other formulations containing 
different amounts of SA (i.e. SA 0.25, 0.50 and 0.75), with the composite films showing a 
decrease in swelling as SA concentration increased. The higher swelling index of HPMC-SA 
wafers in comparison to HPMC-SA films can be attributed to the sponge-like pores in the 
internal structure as shown in SEM image and by the pore analysis data, with increase in 
porosity as SA increased in the formulations, which permits rapid ingress of buffered solution 
into the polymer matrix [11]. The rapid ingress upon contact with buffered solution explains 
the rapid increase of swelling index (%) within 2 mins and then constant swelling index (%) 
with time. This also explains the increase in swelling index as SA increased in wafers but 
with an opposite effect in the films. This difference in swelling behaviour of films and 
wafers, has been previously reported [18, 28]. 
The mucoadhesion results of HPMC-SA films and wafers demonstrate increase in 
adhesive properties as SA increased and with the addition of NIC in all HPMC-SA films and 
wafers. This can be attributed to hydrogen bonding (SA) and electrostatic interaction (NIC) 
with mucin [32]. Charged bioadhesive polymers have been shown to increase mucoadhesion 
as the polymer charge interacts with the surface charge of mucin thereby leading to stronger 
bonding [33]. However, HPMC-SA films demonstrated higher adhesive properties than 
HPMC-SA wafers due to better initial contact, which could enable better hydrogen bonding 
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and high affinity of liquid to solid (wetting theory) [34]. HPMC-SA films also contained 
GLY with hydrogen bonding OH groups group, which can further improve the interaction of 
both BK and DL HPMC-SA films with the model buccal mucosal surface (i.e. gelatine 
equilibrated with mucin).  
HPMC-SA wafers demonstrated more diffusion of solvent (swelling) and therefore 
could be expected to follow diffusion theory, than hydrogen bonding which is the result of 
limited contact surface area from its sponge-like nature leading to liquid to solid affinity. 
However, introduction of NIC improved bonding during mucoadhesion by introducing 
electrostatic ionic groups, which enhanced interaction of the formulations with mucin 
resulting in an increase in mucoadhesion of DL HPMC-SA film and wafers [35]. 
NIC loading efficiency is important in selecting optimised dosage form (films/wafers) 
for NRT. The main challenge of dealing with the free base form of NIC is its volatility. The 
drug loading efficiency of NIC was higher in HPMC-SA wafers than films because in the 
case of films, NIC experienced evaporation during the drying process in the oven at higher 
temperature [15]. The improved drug loading efficiency in HPMC-SA wafers is due the 
freeze-drying cycle, which allowed use of lower temperatures below 25°C compared to 
HPMC-SA films with a drying temperature of 30°C. Therefore, in this study HPMC-SA films 
were not considered further for in vitro drug dissolution. 
The rapid drug release shown in the dissolution profiles of HPMC-SA wafers could 
be due to water-uptake by diffusion of dissolution media into HPMC-SA wafers due to the 
sponge-like porous internal structure of the wafers. The rate of drug release in the composite 
HPMC-SA wafers was higher in wafers containing highest SA concentration and could be 
explained using the swelling results of HPMC-SA wafers which demonstrated a higher 
swelling index for wafers with maximum SA concentration. The HPMC-SA wafers 
demonstrated the highest swelling index at SA 0.75 and the lowest swelling index at SA 0.25. 
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This can be correlated to the drug release as SA 0.75 showed rapid drug release while SA 
0.25 formulation showed the slowest rate of release of drug from the polymer matrix. The 
relationship between the release profile and the swelling profile can be attributed to the 
porosity of the polymer matrix as shown in the SEM images and pore analysis because SA 
0.75 formulation showed the highest porosity. Furthermore, the porosity can also be 
explained by the mechanical properties of the wafer as increase in porosity decreases the 
resistance to compression. The release of more than 90% of NIC within 30 mins is expected 
to be effective in rapid delivery of NIC to brain receptors and hence increase dopamine levels 
resulting in a pleasurable feeling similar to that of smoking [36]. 
 
5 Conclusions 
 HPMC-SA composite films and wafers have been optimised and compared as potential 
dosage forms for NRT. The two dosage forms demonstrated different characteristics in their 
physical properties (mechanical, surface/internal morphology and thermal properties), 
swelling index, mucoadhesion, drug loading capacity and drug release. HPMC-SA composite 
wafers showed a porous in internal morphology, higher mucoadhesion, swelling index and 
drug loading capacity than HPMC-SA composite films. SA polymer used in the development 
of HPMC-SA composite wafers modified and improved properties of HPMC at optimum SA 
concentration and hence can be utilised as a drug delivery system for NRT. The polymeric 
composite system comprising HPMC and SA can be effective in enhancing the functional 
properties of buccal NRT to achieve desired optimum characteristics as an improvement over 
the currently used chewing gum which is difficult to control in terms of drug release. 
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Figure Legends 
Figure 1 Mechanical (tensile) profiles of HPMC films showing the effect of GLY 
concentrations on: (a) Tensile strength, (b) elastic modulus and (c) Elongation at break. 
 
Figure 2 Mechanical (tensile) properties of BK and DL HPMC-SA composite films showing 
effect of changing SA content on (a) tensile strength (b) elongation at break and (c) elastic 
modulus. 
 
Figure 3 Hardness profiles of BK and DL HPMC-SA composite wafers showing the 
resistance to compression deformation with changing SA content. 
 
Figure 4 (i) Surface morphology of HPMC films at different GLY concentrations: (a) 0.0% 
w/v, (b) 0.5% w/v, (c) 1.0% w/v, (d) 2.0% w/v, (e) 3.0% w/v and (f) 4.0% w/v. (ii) SEM 
images of composite HPMC-SA films with different SA content (a) SA 0.00 (b) SA 0.25 (c) 
SA 0.50 (d) SA 0.75. 
 
Figure 5 SEM images of HPMC-SA wafers (a) SA 0.00 (b) SA 0.25 (c) SA 0.50 (d) SA 0.75 
 
Figure 6 XRD-transmission diffractograms of (a) pure powders (b) BK HPMC-SA composite 
films (c) DL HPMC-SA composite films (d) BK HPMC-SA composite wafers (e) DL 
HPMC-SA composite wafers. 
 
Figure 7 ATR-FTIR spectra of (a) pure polymers, GLY, NIC (b) BK HPMC-SA composite 
films, (c) DL HPMC-SA composite films (d) BK HPMC-SA composite wafers and (e) DL 
HPMC-SA composite wafers. 
 
Figure 8 DSC thermograms of (a) BK HPMC-SA films (b) DL HPMC-SA films (c) BK 
HPMC-SA wafers and (d) DL HPMC-SA wafers 
 
Figure 9 Swelling profiles (i.e. % swelling index against time) of (a) composite HPMC-SA 
films and (b) composite HPMC-SA wafers. 
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Figure 10 Mucoadhesive profiles of BK and DL composite films: (a) peak adhesive force (N) 
(b) total work of adhesion (Nmm) (c) cohesiveness (mm). 
 
Figure 11 Mucoadhesive profiles of BK and DL composite wafers: (a) peak adhesive force 
(b) total work of adhesion (c) cohesiveness. 
 
Figure 12 In vitro drug release profiles of DL HPMC-SA composite wafers. 
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Table 1: Composition of (a) selected polymers, plasticizer and drug used in composite 
polymeric solutions for film formulations and (b) selected polymers and drug used in 
polymeric solutions for freeze-dried composite wafer formulations. 
(a) 
Sample 
name 
HPMC 
(% w/v) 
SA 
(% w/v) 
GLY 
(% w/v) 
NIC 
(g) 
Total excipient content in 
polymeric solution 
(% w/v) 
BK SA 0.00 2.00 0.00 2.00 0.00 4.00 
BK SA 0.25 1.75 0.25 2.00 0.00 4.00 
BK SA 0.50 1.50 0.50 2.00 0.00 4.00 
BK SA 0.75 1.25 0.75 2.00 0.00 4.00 
DL SA 0.00 2.00 0.00 2.00 0.20 4.00 
DL SA 0.25 1.75 0.25 2.00 0.20 4.00 
DL SA 0.50 1.50 0.50 2.00 0.20 4.00 
DL SA 0.75 1.25 0.75 2.00 0.20 4.00 
 
(b) 
Sample name HPMC 
(% w/v) 
SA 
(% w/v) 
NIC 
(g) 
Total excipient content in 
polymeric solution (% w/v) 
 BK SA 0.00 2.00 0.00 0.00 2.00 
BK SA 0.25 1.75 0.25 0.00 2.00 
BK SA 0.50 1.50 0.50 0.00 2.00 
BK SA 0.75 1.25 0.75 0.00 2.00 
DL SA 0.00 2.00 0.00 0.20 2.00 
DL SA 0.25 1.75 0.25 0.20 2.00 
DL SA 0.50 1.50 0.50 0.20 2.00 
DL SA 0.75 1.25 0.75 0.20 2.00 
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Figure 10 
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Figure 11 
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